Correlation Between Blueprint Medicines and Structure Therapeutics
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Structure Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Structure Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and Structure Therapeutics American, you can compare the effects of market volatilities on Blueprint Medicines and Structure Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Structure Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Structure Therapeutics.
Diversification Opportunities for Blueprint Medicines and Structure Therapeutics
-0.15 | Correlation Coefficient |
Good diversification
The 3 months correlation between Blueprint and Structure is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Structure Therapeutics America in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Structure Therapeutics and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Structure Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Structure Therapeutics has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Structure Therapeutics go up and down completely randomly.
Pair Corralation between Blueprint Medicines and Structure Therapeutics
Given the investment horizon of 90 days Blueprint Medicines Corp is expected to generate 0.65 times more return on investment than Structure Therapeutics. However, Blueprint Medicines Corp is 1.54 times less risky than Structure Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Structure Therapeutics American is currently generating about -0.13 per unit of risk. If you would invest 9,027 in Blueprint Medicines Corp on August 25, 2024 and sell it today you would earn a total of 388.00 from holding Blueprint Medicines Corp or generate 4.3% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Blueprint Medicines Corp vs. Structure Therapeutics America
Performance |
| Timeline |
| Blueprint Medicines Corp |
| Structure Therapeutics |
Blueprint Medicines and Structure Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Blueprint Medicines and Structure Therapeutics
The main advantage of trading using opposite Blueprint Medicines and Structure Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Structure Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will offset losses from the drop in Structure Therapeutics' long position.| Blueprint Medicines vs. Eliem Therapeutics | Blueprint Medicines vs. HCW Biologics | Blueprint Medicines vs. Scpharmaceuticals | Blueprint Medicines vs. Milestone Pharmaceuticals |
| Structure Therapeutics vs. Day One Biopharmaceuticals | Structure Therapeutics vs. X4 Pharmaceuticals | Structure Therapeutics vs. Inozyme Pharma | Structure Therapeutics vs. Acumen Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Complementary Tools
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |